Your browser doesn't support javascript.
loading
Recent advances in TRPV4 agonists and antagonists.
Lawhorn, Brian G; Brnardic, Edward J; Behm, David J.
Afiliação
  • Lawhorn BG; Medicinal Chemistry, Medicine Design, and Early Development Leaders, Research, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, United States. Electronic address: brian.2.lawhorn@gsk.com.
  • Brnardic EJ; Medicinal Chemistry, Medicine Design, and Early Development Leaders, Research, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, United States.
  • Behm DJ; Medicinal Chemistry, Medicine Design, and Early Development Leaders, Research, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, United States.
Bioorg Med Chem Lett ; 30(8): 127022, 2020 04 15.
Article em En | MEDLINE | ID: mdl-32063431
ABSTRACT
TRPV4 is a ubiquitously expressed, non-selective cation channel activated by a range of stimuli including hypotonicity, temperature, pH, stretch and endogenous ligands. Agents that modulate TRPV4 are sought as potential therapeutics for the treatment of many diseases including osteoarthritis, respiratory illnesses, gastrointestinal disorders, pain and congestive heart failure. In recent years, significant advances in TRPV4 drug discovery have been realized as at least seven novel TRPV4 agonist or antagonist templates were reported and the first selective TRPV4 antagonist was evaluated in early clinical trials.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Produtos Biológicos / Forbóis / Canais de Cátion TRPV Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Produtos Biológicos / Forbóis / Canais de Cátion TRPV Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article